CTRI/2020/10/028250Other2 期
A Randomized, Controlled, Open Label, Multicentre, Two Arm, Two Dosage, Phase II StudyAssessing the Efficacy and Safety of Intravenous Administration of Adult Human Bone MarrowDerived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells in Patients with AcuteRespiratory Distress Syndrome Caused by Pneumonia due to COVID-19
ICMR0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- Other
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients must satisfy all of the following criteria to be included in the
- •1. Males or females of age 18 to 65 years of Indian origin and diagnosed with COVID-19 by reverse transcription polymerase chain
- •reaction (RT-PCR) assay.
- •2. Informed consent by the patient or his/her legal representative in case the patient is not capable of giving the consent.
- •3. Patients diagnosed with COVID-19 pneumonia causing moderate and severe ARDS as per the Berlin ARDS definition.
- •a. Respiratory failure within one week of a known insult or new and/or worsening respiratory symptoms
- •b. Respiratory failure not fully explained by cardiac function or volume overload
- •c. Moderate to severe hypoxemia must be present, defined as the
- •ratio of PaO2/FiO2 on at least PEEP 5cmH2O:
- •i Moderate ARDS: PaO2/FiO2 >100 mmHg and ?200 mmHg, on
- •ventilator settings that include PEEP ?5 cm H2O OR
- •ii Severe ARDS: PaO2/FiO2 ?100 mmHg on ventilator settings that include PEEP ?5 cm H2O
- •d. Bilateral opacities in chest X-ray or CT scan.
- •4. Patients requiring mechanical ventilatory support.
- •5. Patients who can start receiving BMMSCs within 72 hours (3 days) after the diagnosis of ARDS.
排除标准
- •Patients may not be selected if any of the following criteria are
- •1. Any other cause of ARDS not attributable to SARS-CoV2.
- •2. Patients whose life expectancy is < 6 months because of other causes other than the respiratory failure.
- •3. Presence of any active
- •malignancy.
- •4. Any end stage organ disease as assessed by investigator which may possibly affects the safety of the study drug.
- •5. Patient with history of any stem cell transplant in the past.
- •6. Moderate to severe liver failure (Child â?? Pughâ??s score > 12).
- •7. Patient with chronic respiratory disease or use of home oxygen therapy or use of ventilator at home.
- •8. Patients for whom one week or longer has passed since the attachment of ventilator.
- •9. Patient with pulmonary transplant or having history of lung lobectomy.
- •10. Patient with clinically findings consistent with diffuse alveolar haemorrhage.
- •11. Patients with mean arterial (blood)pressure 12. Patients who are appropriate to be treated with extracorporeal membrane oxygenation
- •(ECMO) at screening or currently receiving ECMO.
- •13. Patients who were resuscitated after cardio-respiratory arrest.
- •14. Patients with uncontrolled co-morbidities like hypertension,diabetes mellitus etc., as per investigator discretion
- •15. Patients who are under artificial dialysis at screening.
- •16. Patient documented to have deep venous thrombosis or pulmonary embolism within last 3 months.
- •17. Patients with a history of myocardial infarction within 6 months before screening.
- •18. Women of childbearing age who are not using an adequate method of contraception. If the patient is menopausal, it must be documented.
- •19. Pregnancy or breast feeding.
- •20. Patient with HIV infection.
- •21. Patient expected to have hypersensitivity for the study drug and/or excipients.
研究者
相似试验
已完成
4 期
A Clinical study on treatment of 1% Pimecrolimus topical cream versus 1% Elidel topical cream in a multiple hospitals randomly distributed Atopic Dermatitis patients in IndiaCTRI/2011/11/002179Biocon Limited246
进行中（未招募）
1 期
Safety and Efficacy Study of HGT-1410 Administration in Pediatric Patients with Early Stage of Sanfilippo Syndrome Type ASanfilippo Syndrome Type A or Mucopolysaccharidosis (MPS IIIA)MedDRA version: 14.1Level: LLTClassification code 10056918Term: Sanfilippo's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: PTClassification code 10056890Term: Mucopolysaccharidosis IIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2013-003450-24-ESShire Human Genetic Therapies, Inc18
已完成
2 期
A Randomized, Controlled, Open-label, Multicenter, Phase IIb Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration via an Intrathecal Drug Delivery Device in Pediatric Patients with Early Stage Mucopolysaccharidosis Type IIIA DiseasemucopolysaccharideSanfilippo syndrome10000546NL-OMON40318Shire2
进行中（未招募）
1 期
Safety and Efficacy Study of HGT-1410 Administration in Pediatric Patients with Early Stage of Sanfilippo Syndrome Type AEUCTR2013-003450-24-GBShire Human Genetic Therapies, Inc21
进行中（未招募）
1 期
A Study of Ibrutinib in Combination With Rituximab Versus Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab, in Relapsed/Refractory Mantle Cell LymphomaRelapsed or Refractory Mantle Cell LymphomaMedDRA version: 20.0Level: HLTClassification code 10026798Term: Mantle cell lymphomasSystem Organ Class: 100000004851EUCTR2022-000364-21-CZJanssen-Cilag International NV490